Oppenheimer Holdings Analysts Lower Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Oppenheimer Holdings dropped their Q3 2018 earnings per share estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Sunday. Oppenheimer Holdings analyst D. Archila now anticipates that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.03. Oppenheimer Holdings currently has a “Buy” rating and a $26.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.07 EPS and FY2019 earnings at $0.36 EPS.

A number of other research analysts have also weighed in on VNDA. ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Tuesday, October 24th. Finally, Piper Jaffray Companies set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Vanda Pharmaceuticals has an average rating of “Buy” and a consensus target price of $22.00.

ILLEGAL ACTIVITY NOTICE: “Oppenheimer Holdings Analysts Lower Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/31/oppenheimer-holdings-analysts-lower-earnings-estimates-for-vanda-pharmaceuticals-inc-vnda.html.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 0.472% during trading on Tuesday, reaching $15.825. The company’s stock had a trading volume of 177,324 shares. Vanda Pharmaceuticals has a 12 month low of $12.70 and a 12 month high of $18.99. The stock’s 50 day moving average price is $17.04 and its 200-day moving average price is $15.81. The firm’s market cap is $709.88 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.01 earnings per share.

A number of institutional investors have recently bought and sold shares of the business. Rice Hall James & Associates LLC lifted its stake in Vanda Pharmaceuticals by 1.0% in the second quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 279 shares during the last quarter. American International Group Inc. lifted its stake in Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares during the last quarter. California Public Employees Retirement System lifted its stake in Vanda Pharmaceuticals by 3.8% in the second quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 2,200 shares during the last quarter. Legal & General Group Plc lifted its stake in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the last quarter. Finally, Voya Investment Management LLC lifted its stake in Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the last quarter. 86.52% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit